Market News

Latest financial and economic news and analysis

Zacks Investment Research News Agency
6 days ago•Zacks Investment Research
Stocks Medium Importance Neutral
5 Attractively Valued Low P/S Stocks With Solid Revenue Potential

5 Attractively Valued Low P/S Stocks With Solid Revenue Potential

Stocks with low P/S ratios, solid fundamentals and revenue potential offer opportunities amid improving business momentum. M, PEB, BCC, APLE and PBF are attractively valued.

Related Symbols 1
APLE APLE
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Proactive Investors News Agency
6 days ago•Proactive Investors
Stocks Medium Importance Neutral
First Phosphate secures federal backing for infrastructure development at Quebec phosphate project

First Phosphate secures federal backing for infrastructure development at Quebec phosphate project

First Phosphate Corp. (CSE:PHOS, OTCQX:FRSPF, FRA:KD0, OTC:FPHOY) announced that it has finalized agreements for $4.84 million in non-repayable funding from the Government of Canada through Natural Resources Canada's First and Last Mile Fund to support infrastructure development for its Bégin-Lamarche phosphate deposit in Quebec. The funding includes approximately $3.07 million for a study focused on clean energy infrastructure, including the site selection, connection corridors, feasibility work and design of a 161-kilovolt transmission line and substations in the Saguenay-Lac-Saint-Jean region.

Related Symbols 1
PHOS PHOS
Source: Proactive Investors
Visit Source
0 0 0
Read More
Comment
PYMNTS News Agency
6 days ago•PYMNTS
Stocks Medium Importance Neutral
Circle Wants AI Payments to Create an Entirely New Stablecoin Market

Circle Wants AI Payments to Create an Entirely New Stablecoin Market

Circle's latest earnings suggest USDC is beginning to separate from the crypto cycle just as autonomous software agents create a potentially new market for digital payments. But the company's second quarter 2026 earnings call Wednesday (Aug.

Related Symbols 1
CRCL CRCL
Source: PYMNTS
Visit Source
0 0 0
Read More
Comment
Forbes News Agency
6 days ago•Forbes
Stocks Medium Importance Neutral
Here's What Analysts Are Saying About SpaceX: Earnings Report Sends Stock Down 9%

Here's What Analysts Are Saying About SpaceX: Earnings Report Sends Stock Down 9%

Some brokerages appeared optimistic about SpaceX's quarterly earnings: JPMorgan analysts, who lifted their price target for shares to $240 from $225, wrote SpaceX is benefiting from “extreme vertical integration” while noting its “pace of change in AI is incredibly fast,” and that a step-up in AI infrastructure and higher monetization could push SpaceX's AI revenue to $100 billion in 2027. Wells Fargo analysts cut their price target for SpaceX shares to $215 from $230 amid broader caution about its AI spending, noting that SpaceX was “off to an ambitious start” and that revenue projections for 2027 and 2028 were higher than expected, but so were capital expenditure estimates.

Related Symbols 1
SPCX SPCX
Source: Forbes
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
6 days ago•Zacks Investment Research
Stocks Medium Importance Neutral
Lumen Posts Narrower-Than-Expected Q2 Loss, Revenues Drop Y/Y

Lumen Posts Narrower-Than-Expected Q2 Loss, Revenues Drop Y/Y

LUMN's Q2 loss came in narrower than expected as strategic revenues have risen 14.1% and free cash flow has turned positive despite a 9.3% revenue decline.

Related Symbols 1
LUMN LUMN
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Proactive Investors News Agency
6 days ago•Proactive Investors
Stocks Medium Importance Neutral
CVS Health tops second-quarter estimates, raises full-year profit outlook

CVS Health tops second-quarter estimates, raises full-year profit outlook

CVS Health Corp (NYSE:CVS) reported second-quarter revenue and profit that beat Wall Street estimates on Wednesday, and raised its full-year adjusted earnings guidance, though cautious guidance pressured shares. Revenue rose 7.3% year-over-year to $106.1 billion, above analyst estimates of $100.11 billion.

Related Symbols 1
CVS CVS
Source: Proactive Investors
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment